Table 4.
Markers significantly different between patients with MPS I and age-matched control subjects at 10 years’ follow-up (n = 29)
| Marker | Adjusted P | Fold change | Pathway |
|---|---|---|---|
| CCL19 | .04 | 1.4 | Pro-inflammatory |
| CCL20 | .01 | 1.6 | Pro-inflammatory |
| CD244 | .004 | 2.2 | Pro-inflammatory |
| CD40 | .01 | 1.8 | Pro-inflammatory |
| CD5 | .006 | 2.1 | Pro-inflammatory |
| CD6 | .002 | 2.6 | Pro-inflammatory |
| CD8A | .004 | 2.5 | Pro-inflammatory |
| CDCP1 | .02 | 1.3 | Pro-inflammatory |
| CX3CL1 | .01 | 1.7 | Pro-inflammatory |
| CXCL5 | .004 | 2.3 | Pro-inflammatory |
| IL.12B | .003 | 2.2 | Pro-inflammatory |
| IL.18R1 | .03 | 1.7 | Pro-inflammatory |
| IL7 | .001 | 2.0 | Pro-inflammatory |
| MCP.2 | .02 | 1.6 | Pro-inflammatory |
| MCP.4 | .008 | 1.7 | Pro-inflammatory |
| TNFB | .05 | 1.4 | Pro-inflammatory |
| LAP.TGF.β.1 | .03 | 1.6 | Anti-inflammatory |
| IL.10RB | .01 | 1.7 | Anti-inflammatory |
| RANKL | .001 | 2.7 | Bone homeostasis |
| OPG | .001 | 2.8 | Bone homeostasis |
| AXIN1 | .002 | 3.2 | Bone homeostasis |
| SCF | .0005 | 3.5 | Growth factor/bone homeostasis |
| Flt3L | .0002 | 2.8 | Growth factor/bone homeostasis |
| CSF.1 | .004 | 2.2 | Growth factor/bone homeostasis |
| DNER | .001 | 2.5 | Growth factor/bone homeostasis |
| LIF.R | .006 | 1.5 | Growth factor |
| TRAIL | .03 | 1.8 | Apoptosis/bone homeostasis |
| TWEAK | .001 | 2.3 | Apoptosis |
| MMP.10 | .01 | 1.9 | ECM degradation |
ECM, extracellular matrix.
The markers that were both significant and included a log2 fold change >1.5 are highlighted in bold.